What is the recommended acute management for an ischemic stroke affecting the middle cerebral artery (MCA)?

Acute Management of MCA Ischemic Stroke

For acute ischemic stroke affecting the middle cerebral artery, immediately administer IV alteplase (0.9 mg/kg, max 90 mg) if the patient presents within 4.5 hours of symptom onset and has no contraindications, followed by mechanical thrombectomy with stent retrievers for proximal MCA (M1) occlusions within 6 hours if NIHSS ≥6 and ASPECTS ≥6. 1

Time-Critical Treatment Algorithm

Within 0-4.5 Hours: IV Thrombolysis

• Administer IV alteplase immediately without waiting to assess clinical response before considering endovascular therapy 2
• Dosing: 0.9 mg/kg (maximum 90 mg) over 60 minutes with 10% as initial bolus over 1 minute 1
• Blood pressure must be safely lowered to <185/110 mm Hg before starting alteplase 1
• Do not delay alteplase even if mechanical thrombectomy is planned - patients eligible for IV thrombolysis should receive it regardless of endovascular considerations 2

Key eligibility criteria:

• Within 3 hours: All ages, any severity, even severe strokes benefit despite higher hemorrhagic risk 1
• 3-4.5 hour window: Age ≤80 years, no history of both diabetes AND prior stroke, NIHSS ≤25, not on oral anticoagulants, no imaging evidence of >1/3 MCA territory involvement 1

Within 0-6 Hours: Mechanical Thrombectomy

Proceed directly to mechanical thrombectomy with stent retrievers if ALL criteria met: 2

• Prestroke mRS 0-1 (functionally independent)
• Proximal MCA (M1) or ICA occlusion confirmed on imaging
• Age ≥18 years
• NIHSS ≥6
• ASPECTS ≥6 (limited early ischemic changes)
• Groin puncture achievable within 6 hours of symptom onset

Critical technical points:

• Target TICI 2b/3 reperfusion (substantial to complete recanalization) 2
• Use stent retrievers as first-line device (superior to older MERCI devices) 2
• Consider proximal balloon guide catheter or large-bore distal access catheter with stent retrievers for better outcomes 2

MCA-Specific Considerations

Proximal vs. distal MCA occlusions matter significantly:

• M1 (proximal MCA) occlusions: Class I recommendation for thrombectomy within 6 hours 2
• M2/M3 (distal MCA) occlusions: May be reasonable but benefits uncertain (Class IIb) - requires careful patient selection 2

Research demonstrates that MCA occlusions achieve 88% recanalization rates with IV alteplase compared to only 31% for ICA occlusions, with correspondingly better early neurological outcomes 3. This supports aggressive treatment of isolated MCA occlusions.

Blood Pressure Management

During and after mechanical thrombectomy:

• Maintain BP ≤180/105 mm Hg during procedure and for 24 hours afterward 1
• If successful reperfusion achieved, keeping BP <180/105 mm Hg may be reasonable 1

Antiplatelet Therapy

• Administer aspirin 160-300 mg within 24-48 hours after stroke onset 1
• If IV alteplase given, delay aspirin until 24 hours post-thrombolysis 1
• Exception: May give earlier if compelling indication where withholding poses substantial risk 1

Critical Pitfalls to Avoid

1. Do NOT observe patients after IV alteplase to assess response before pursuing thrombectomy - this delays definitive treatment and worsens outcomes (Class III recommendation) 2

2. Time is brain: Every 15-minute delay in reperfusion significantly worsens outcomes. Initiate treatment as rapidly as possible within therapeutic windows 1, 2

3. Contraindications for alteplase beyond 4.5 hours: Do not give IV thrombolysis if unclear symptom onset time or patient last known well >4.5 hours ago 1

4. Beware of rare vascular anomalies: Twig-like or aplastic MCA can mimic M1 occlusion on non-invasive imaging but carries high hemorrhagic risk with thrombectomy 4

Uncertain Benefit Scenarios (Proceed with Caution)

May consider thrombectomy but benefits uncertain (Class IIb):

• Prestroke mRS >1, ASPECTS <6, or NIHSS <6 with M1/ICA occlusion 2
• Treatment beyond 6 hours from symptom onset 2
• Contraindications to IV alteplase (reasonable to proceed with thrombectomy alone within 6 hours) 2

The most recent 2026 AHA/ASA guideline 5 emphasizes continued evolution in thrombolytic eligibility and thrombectomy determination, though the core time-dependent treatment paradigm remains unchanged from the 2018 guidelines 1.